Thank You...

...for attending CEU Seattle, we are excited that you and your colleagues decided to join us for this comprehensive clinical endocrine program.

CEU 2019 Seattle (20.75 points) is certified for both AMA PRA Category 1 Credit(s)™ and ABIM MOC points.

Provide your feedback and claim your CME/MOC credit here

For access to all of the meeting materials please use the mobile app. You can get the app on Google Play or download it in the Apple App Store. Please note, you must log in to the app using your endocrine.org account information (email and password) to view the presentation slides.


CEU Session Recordings Now Available

As a reminder, your registration includes access to CEU 2019 Session Recordings, which are now accessible on your computer, tablet, or on the go with downloadable MP3.

These recordings will allow you to revisit the world-class education you received onsite, and you can earn an additional 28.25 AMA PRA Category 1 Credits™. Access these sessions by logging in with your endocrine.org account information (email and password).


CEU 2019 Supporters

The Endocrine Society would like to thank the following for their support:

  • Corcept Therapeutics
  • Exelixis
  • Lilly USA
  • Merck & Co.
  • Strongbridge Biopharma
  • Xeris Pharmaceuticals


CEU 2019 Exhibits

Aegerion Pharmaceuticals (Table 20)—Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.

Alexion (Table 12)—Hypophosphatasia (HPP) is an inherited, systemic, progressive disease with a life long impact. HPP can have devastating consequences for patients of any age. HPP is caused by a deficiency in Alkaline Phosphatase.

Amgen (Table 17 & 22)—Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.

Benaroya Research Institute & TrialNet (Table 25)—Benaroya Research Institute (BRI), a nonprofit research group under Virginia Mason, is at the forefront of autoimmune disease research. BRI is also home to Type 1 Diabetes TrialNet, an international network of clinical studies attempting to understand, treat, stop the progression of Type 1 Diabetes - and eventually, reverse it.

Boehringer Ingelheim (Table 14)—Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim.

Companion Medical (Table 11)—Companion Medical is a leader in advanced technology to improve diabetes care. InPen is the first and only FDA-cleared smart pen for insulin delivery.

Corcept Therapeutics (Table 10)— Corcept is a pharmaceutical company engaged in the discovery, and development of drugs that treat metabolic and oncologic disorders by modulating the effects of cortisol.

Crinetics Pharmaceuticals (Table 13)—Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Sponsor
Doximity (Table 9)—Doximity is the largest social network for healthcare professionals, with over 1 million members. Our free app offers services such as referrals, HIPAA secure faxing/messaging, CME, privately calling patients from your cell phone, and more. Over 80% of all US physicians are a part of Doximity.

Esaote North America (Table 5)—Esaote prides itself in achieving superior price and performance in diagnostic ultrasound systems. Come learn about the NEW MyLab X5, NEW MyLabX7 and NEW MyLab Omega featuring advanced image quality with the highest level of performance, up to a 22mhz probe, extended connectivity, and a full screen mode capability.

Feel Good, Inc (Table 23)—Feel Good Inc. provides employee wellness solutions. We provide a non-invasive approach of pain management for stress, tension, nerve and muscle pain.

Horizon Therapeutics (Table 6 & 7)—Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.

Hormone Health Network (Table 15)—The Hormone Health Network (HHN) is the Endocrine Society’s patient education affiliate and the global leader in endocrine patient education. The Network offers health care providers accurate, time-saving tools and gives patients the trusted information they need to better understand their conditions and treatment options as well as have informed discussions with their health care providers. Together, HHN’s goal is to positively impact the health and well-being of patients by moving them from educated to engaged, and from informed to active partners in their own health care.

HRA Pharma Rare Diseases (Table 1)—HRA Pharma Rare Diseases is “Devoted to the Rare,” marketing approved products used to diagnose and treat rare endocrine diseases.

Lilly (Table 19)—We are committed to supporting you and your family in every step of your journey with diabetes. Living a long and healthy life with diabetes is possible with proper treatment, diet, and exercise. Through our medicines, resources, and support programs, Lilly helps make life better for people with diabetes.

Novo Nordisk (Table 3 & 4)—Novo Nordisk, a global health care company, is committed to discovering and developing innovative medicines to help people living with diabetes lead longer, healthier lives.

Pfizer Inc. (Table 2)—At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.

Sponsor
Progenics Pharmaceuticals (Table 18)—Progenics Pharmaceuticals, Inc. is an oncology company focused on the development and commercialization of innovative targeted medicines and other technologies to target and treat cancer.

Strongbridge for Novo Nordisk (Table 8)—Macrilen is the first and only FDA approved oral test for diagnosing people with Adult Growth Hormone Deficiency

Takeda Pharmaceutical (Table 21)—Takeda provides better health and a brighter future.

Veracyte (Table 16)—The Afirma Genomic Sequencing Classifier and Xpression Atlas provide physicians with a comprehensive solution for a complex landscape in thyroid cancer diagnosis and individualization of care. The combined offering enables physicians to answer multiple clinical questions for their thyroid patients using a single, minimally invasive fine needle aspiration (FNA) sample.


Cancellation Policy

Cancellations must be received in writing by August 5, 2019. No refunds will be issued after that date.
All cancellations are subject to a $75 processing charge.